Specialty Chemicals

Celanese

Celanese Announces Q3 EPS Guidance, RBC Raises Target Price

JPMorgan Raises Celanese's Target Price to $68

Evercore ISI analyst maintains Celanese hold rating

CFRA Maintains Sell Rating on Celanese with Raised Target Price

Celanese released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 2.337 B (forecast USD 2.347 B), actual EPS USD 0.4009 (forecast USD 0.8798)

Celanese Adjusts Nylon Business Plan

Celanese to Report Q1 Earnings, Analysts Project EPS of 88 Cents

Morgan Stanley Raises Celanese Target Price to $72

Celanese to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 2.347 B, EPS USD 0.8798

Wells Fargo Raises Target Price on Celanese Corporation, Shares Up 7.6%

Celanese Under Scrutiny Due to Board Resignation and Disappointing Earnings

Lloyd Harbor Capital Management Establishes New Position in Celanese

Celanese Announces Global Price Increase for Acetyl Chain

Celanese Announces Increase in Engineering Materials Prices

Celanese Corporation 2025 Fiscal Year Revenue Misses Expectations

Muhlenkamp & Co. Inc. Increases Stake in Celanese Corp.

Celanese Corp. Receives Mixed Analyst Ratings with Raised Target Price

Celanese released FY2025 annual earnings on February 17 After-Market (EST), actual revenue USD 9.544 B (forecast USD 9.583 B), actual EPS USD -10.6392 (forecast USD -9.81)

Celanese released FY2025 Q4 earnings on February 17 After-Market EST, actual revenue USD 2.204 B (forecast USD 2.249 B), actual EPS USD 0.1733 (forecast USD 0.8835)

Celanese Announces Q4 Earnings and Q1 Outlook

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Celanese Corp. (CE) shares fell 4.05% to $53.49 on Tuesday, marking the fourth consecutive day of losses. The stock is now 24.34% below its 52-week high of $70.70. In contrast, competitors like Avantor Inc. (AVTR) rose 0.53%, while Westlake Corp. (WLK) and Huntsman Corp. (HUN) saw declines of 3.06% and 3.55%, respectively. The overall market also declined, with the S&P 500 down 0.67%.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Avantor

Westlake

Hunstman

Factset Research

Celanese Corp. Stock Underperforms Tuesday When Compared To Competitors

Celanese Corporation (NYSE: CE) has announced a price increase for various engineered materials products, effective June 1, 2026, due to market developments and supply chain disruptions. The increases vary by product and region, with specific amounts listed for different materials. Celanese emphasizes its capability to support customers through its supply chain and innovation centers.

MorningStar

Celanese Announces Engineered Materials Price Increase

Celanese Corp. (CE) shares fell 1.85% to $55.75 on Monday, marking the third consecutive day of losses. The stock is currently 21.15% below its 52-week high of $70.70. In comparison, competitors like Avantor Inc. (AVTR) and Westlake Corp. (WLK) had mixed performances, with WLK rising 3.24%. Trading volume was 1.2 million below the 50-day average.

Celanese Corp. Stock Underperforms Monday When Compared To Competitors

MTDR

PAAS

Top Wall Street analysts upgraded Matador Resources (MTDR) from Hold to Buy with a price target increase from $60 to $67, Celanese (CE) from Neutral to Overweight with a price target of $68, and Pan American Silver (PAAS) from Hold to Buy with a price target increase from $67 to $72. Analyst ratings reflect positive outlooks for these stocks, with MTDR closing at $56.97, CE at $58.85, and PAAS at $61.84.

benzinga_article

Matador Resources

Pan American Silver

This Celanese Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday

INCY

Incyte Corp. (INCY) shares rose 1.79% to $100.32 on a strong trading day, outperforming competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin, which saw declines. The S&P 500 and Dow Jones both increased by 0.19%. Incyte's stock is currently 10.66% below its 52-week high of $112.29 reached on January 7th, with trading volume at 1.7 million, surpassing its 50-day average of 1.5 million.

Incyte

VanEck Biotech ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

SPDR S&P Biotech

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Celanese's H2 guidance appears conservative, with RBC Capital Markets noting potential headwinds in its engineered materials business due to inventory drawdowns. The company's H2 EPS guidance of approximately $3.00 may fall short of expectations, while Q2 guidance of about $2.20 is seen as positive. Despite subdued overall demand, there are strengths in specific sectors. RBC has raised its price target to $68 per share from $66, maintaining a sector perform rating. Current stock price is $59.43, up 3.95%.

Fidelity

ROYAL BANK OF CANADA

Celanese's H2 Guide Appears Conservative, RBC Says

Celanese Corp. (CE) shares fell 2.11% to $57.17 on Friday, marking the third consecutive day of losses, despite a generally positive market with the S&P 500 up 0.84%. The stock is 19.14% below its 52-week high of $70.70. In comparison, competitors had mixed results: Avantor Inc. (AVTR) was unchanged, Westlake Corp. (WLK) dropped 3.62%, and Huntsman Corp. (HUN) increased by 1.49%. Trading volume was 2.9 million, above the 50-day average of 2.6 million.

Celanese Corp. Stock Underperforms Friday When Compared To Competitors

Celanese Corp. (CE) shares fell 5.99% to $58.40 on Thursday, marking its second consecutive day of losses amid a declining stock market. The S&P 500 Index decreased by 0.38%, and the Dow Jones Industrial Average dropped by 0.63%. Celanese's stock is now 17.40% below its 52-week high of $70.70 reached on May 5th. In comparison, competitors like Avantor Inc. (AVTR), Westlake Corp. (WLK), and Huntsman Corp. (HUN) also experienced declines, but to a lesser extent. Trading volume for Celanese was 3.0 million, surpassing its 50-day average of 2.6 million.

Celanese Corp. Stock Underperforms Thursday When Compared To Competitors

JPMorgan Chase & Co. has raised its price target for Celanese (NYSE:CE) from $53.00 to $68.00, maintaining a "neutral" rating. This new target suggests a potential upside of 15.80% from the current price. Other analysts have also adjusted their targets, with Robert W. Baird setting it at $75.00 and Wells Fargo at $75.00 as well. Celanese's stock recently traded at $58.72, with a market cap of $6.43 billion. The company reported earnings of $0.85 per share, slightly below expectations, and has a consensus rating of "Hold" with a target of $67.29.

Market Beat

JPMorgan Chase

DuPont de Nemours

Evercore

Wells Fargo

Mizuho Financial

Mizuho Financial Group, Inc.

Morgan Stanley

Bank of America

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

DUPONT DE NEMOURS INC

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Celanese (NYSE:CE) Given New $68.00 Price Target at JPMorgan Chase & Co.

Celanese(CE.US)